Analysis of mucins: Role in laboratory diagnosis

Journal of Clinical Pathology

Volumn 61, Issue 9, 2008, Pages 1018-1024

  Mall, Anwar Suleman ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPITOPE; GLYCOPROTEIN; MEMBRANE PROTEIN; MUCIN; MUCIN 1; MUCIN 4; OLIGOSACCHARIDE; TUMOR MARKER;

ANTIGEN EXPRESSION; ANTIGENICITY; APICAL MEMBRANE; BILE DUCT CARCINOMA; BREAST CANCER; COLORECTAL CANCER; DISEASE MARKER; EPITHELIUM CELL; GEL; HUMAN; LABORATORY DIAGNOSIS; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MOLECULAR WEIGHT; MUCUS; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN SECRETION; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; DIFFERENTIAL DIAGNOSIS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PROCEDURES;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MUCINS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 51349119204     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2008.058057     Document Type: Review

References (135)

1. Allen A. Structure and function of gastrointestinal mucus. In: Johnson LR, ed. Physiology of the gastrointestinal tract. New York: Raven Press, 1981; 359-82.
2. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;86:245-78.
3. Shyu MK, Lin MC, Shih JC, et al. Mucin 15 is expressed in human placenta and suppresses invasion of trophoblast-like cells in vitro. Hum Reprod 2007;22:2723-32.
4. Singh AP, Chaturvedi P, Batra SK. Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res 2007;67:433-6.
5. Porchet N, Dufosse J, Audie JP, et al. Structural features of the core proteins of human airway mucins ascertained by cDNA cloning. Am Rev Respir Dis 1991;144:S15-8.
6. Moniaux N, Nollet S, Porchet N, et al. Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. Biochem J 1999;338:325-33.
7. Moniaux N, Escande F, Batra SK, et al. Alternative splicing generates a family of putative secreted and membrane-associated MUC4 mucins. Eur J Biochem 2000;267:4536-44.
8. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
9. Xing PX, Prenzoska J, Layton GT, et al. Second-generation monoclonal antibodies to intestinal MUC2 peptide reactive with colon cancer. J Natl Cancer Inst 1992;84:699-703.
10. Jonckheere N, Vincent A, Perrais M, et al. The human mucin MUC4 is transcriptionally regulated by caudal-related homeobox, hepatocyte nuclear factors, forkhead box A, and GATA endodermal transcription factors in epithelial cancer cells. J Biol Chem 2007;282:22638-50.
11. Adsay NV. Role of MUC genes and mucins in pancreatic neoplasia. Am J Gastroenterol 2006;101:2330-2.
12. Bergey EJ, Cho MI, Blumberg BM, et al. Interaction of HIV-1 and human salivary mucins. J Acquit Immune Defic Syndr 1994;7:995-1002.
13. Habte HH, Mall AS, de Beer C, et al. The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay. Virol J 2006;3:99.
14. Habte HH, Kotwal GJ, Lotz ZE, et al. Antiviral activity of purified human breast milk mucin. Neonatology 2007;92:96-104.
15. Habte HH, de Beer C, Lotz ZE, et al. Inhibition of human immunodeficiency virus type 1 activity by purified human breast milk mucin (MUC1) in an inhibition assay. Neonatology 2008;93:162-70.
16. Barratt-Boyes SM. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol Immunother 1996;43:142-51.
17. Sangha R, North S. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opin Biol Ther 2007;7:1723-30.
18. Devine PL, McKenzie IF. Mucins: structure, function, and associations with malignancy. Bioessays 1992;14:619-25.
19. Graham RA, Burchell JM, Taylor-Papadimitriou J. The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother 1996;42:71-80.
20. Taylor-Papadimitriou J, Burchell J, Miles DW, et al. MUC1 and cancer. Biochim Biophys Acta 1999;1455:301-13.
21. Mariette C, Piessen G, Leteurtre E, et al. Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase. Surgery 2008;143:58-71.
22. Voynow JA, Selby DM, Rose MC. Mucin gene expression (MUC1, MUC2, and MUC5/5AC) in nasal epithelial cells of cystic fibrosis, allergic rhinitis, and normal individuals. Lung 1998;176:345-54.
23. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60.
24. Hanski C, Riede E, Gratchev A, et al. MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation. Lab Invest 1997;77:685-95.
25. Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999;59:1003-7.
26. Rhodes JM. Usefulness of novel tumour markers. Ann Oncol 1999;10(Suppl 4):118-21.
27. Bast RC Jr, Urban N, Shridhar V, et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002;107:61-97.
28. Jhala N, Jhala D, Vickers SM, et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol 2006;126:572-9.
29. Moniaux N, Andrianifahanana M, Brand RE, et al. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer 2004;91:1633-8.
30. Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 2001;7:4033-40.
31. Balague C, Gambus G, Carrato C, et al. Altered expression of MUC2, MUC4, and MUC5 mucin genes in pancreas tissues and cancer cell lines. Gastroenterology 1994;106:1054-61.
32. Choudhury A, Moniaux N, Winpenny JP, et al. Human MUC4 mucin cDNA and its variants in pancreatic carcinoma. J Biochem 2000;128:233-43.
33. Metzgar RS, Rodriguez N, Finn OJ, et al. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci U S A 1984;81:5242-6.
34. Barnd DL, Lan MS, Metzgar RS, et al. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A 1989;86:7159- 63.
35. Ho JJ. Mucins in the diagnosis and therapy of pancreatic cancer. Curr Pharm Des 2000;6:1881-96.
36. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-86.
37. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32.
38. Nakamura A, Horinouchi M, Goto M, et al. New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol 2002;197:201- 10.
39. Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol 2004;28:839-48.
40. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 1997;47:813-30.
41. Levi E, Klimstra DS, Andea A, et al. MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol 2004;57:456-62.
42. Boland CR, Montgomery CK, Kim YS. A cancer-associated mucin alteration in benign colonic polyps. Gastroenterology 1982;82:664-72.
43. Kannan S, Lakku RA, Niranjali D, et al. Expression of peanut agglutinin-binding mucin-type glycoprotein in human esophageal squamous cell carcinoma as a marker. Mol Cancer 2003;2:38.
44. Imai J, Ghazizadeh M, Naito Z, et al. Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma. Anticancer Res 2001;21:1327-34.
45. Corfield AP, Myerscough N, Longman R, et al. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut 2000;47:589-94.
46. Itzkowitz SH, Bloom EJ, Kokal WA, et al. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990;66:1960-6.
47. Baldus SE, Hanisch FG. Biochemistry and pathological importance of mucin-associated antigens in gastrointestinal neoplasia. Adv Cancer Res 2000;79:201-48.
48. Bresalier RS, Byrd JC, Wang L, et al. Colon cancer mucin: a new ligand for the β-galactoside-binding protein galectin-3. Cancer Res 1996;56:4354-7.
49. Cao Y, Karsten UR, Liebrich W, et al. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cancer 1995;76:1700-8.
50. Giuffre G, Vitarelli E, Tuccari G, et al. Detection of Tn, sialosyl-Tn and T antigens in hereditary nonpolyposis colorectal cancer. Virchows Arch 1996;429:345-52.
51. Itzkowitz SH, Yuan M, Montgomery CK, et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989;49:197-204.
52. Tarp MA, Sorensen AL, Mandel U, et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007;17:197-209.
53. Taylor-Papadimitriou J, Wetzels R, Ramaekers F. Intermediate filament protein expression in normal and malignant human mammary epithelial cells. Cancer Treat Res 1992;61:355-78.
54. Myerscough N, Sylvester PA, Warren BF, et al. Abnormal subcellular distribution of mature MUC2 and de novo MUC5AC mucins in adenomas of the rectum: immunohistochemical detection using non-VNTR antibodies to MUC2 and MUC5AC peptide. Glycoconi J 2001;18:907-14.
55. Gum JR Jr, Hicks JW, Toribara NW, et al. Molecular cloning of human intestinal mucin (MUC2) cDNA. Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor. J Biol Chem 1994;269:2440-6.
56. Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002;295:1726-9.
57. Bresalier RS. Intestinal mucin and colorectal cancer: it's not just goo. Gastroenterology 2002;123:648-9.
58. Bresalier RS, Niv Y, Byrd JC, et al. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest 1991;87:1037-45.
59. Hayashi T, Ishida T, Motoya S, et al. Mucins and immune reactions to mucins in ulcerative colitis. Digestion 2001;63(Suppl 1):28-31.
60. Bartman AE, Sanderson SJ, Ewing SL, et al. Aberrant expression of MUC5AC and MUC6 gastric mucin genes in colorectal polyps. Int J Cancer 1999;80:210-8.
61. Allen A, Hutton DA, Pearson JP. The MUC2 gene product: a human intestinal mucin. Int J Biochem Cell Biol 1998;30:797-801.
62. Biemer-Huttmann AE, Walsh MD, McGuckin MA, et al. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. Clin Cancer Res 2000;6:1909-16.
63. Manne U, Weiss HL, Grizzle WE. Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. Clin Cancer Res 2000;6:4017-25.
64. Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995;129:255-65.
65. Ligtenberg MJ, Buijs F, Vos HL, et al. Suppression of cellular aggregation by high levels of episialin. Cancer Res 1992;52:2318-24.
66. Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 2004;41:189-231.
67. Ellis IO, Hinton CP, MacNay J, et al. Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. Br Med J (Clin Res Ed) 1985;290:881-3.
68. Ellis IO, Bell J, Todd JM, et al. Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. Br J Cancer 1987;56:295-9.
69. Walker JM, Homan EC, Sando JJ. Differential activation of protein kinase C isozymes by short chain phosphatidylserines and phosphatidylcholines. J Biol Chem 1990;265:8016-21.
70. McGuckin MA, Walsh MD, Hohn BG, et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 1995;26:432-9.
71. Luna-More S, Rius F, Weil B, et al. EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas. Pathol Res Pract 2001;197:419-25.
72. Rahn JJ, Dabbagh L, Pasdar M, et al. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973-82.
73. Ceriani RL, Chan CM, Baratta FS, et al. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int J Cancer 1992;51:343-54.
74. Inufusa H, Nakatani Y, Adachi T, et al. Correlation of prognosis of breast cancer patients and expression of Ley which acts as a cofactor of tumor procoagulant. Int J Oncol 1998;13:481-7.
75. Leivonen M, Nordling S, Lundin J, et al. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat 2001;67:15-22.
76. Yamaguchi A, Ding K, Maehara M, et al. Expression of nm23-H1 gene and Sialyl Lewis X antigen in breast cancer. Oncology 1998;55:357-62.
77. Nakagoe T, Fukushima K, Itoyanagi N, et al. Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol 2002;128:257-64.
78. Taylor-Papadimitriou J, Burchell JM, Plunkett T, et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002;7:209-21.
79. Duffy MJ. CA15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 1999;36:579-86.
80. Clinton SR, Beason KL, Bryant S, et al. A comparative study of four serological tumor markers for the detection of breast cancer. Biomed Sci Instrum 2003;39:408-14.
81. Price MR. High molecular weight epithelial mucins as markers in breast cancer. Eur J Cancer Clin Oncol 1988;24:1799-804.
82. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000;86:702-12.
83. Rodriguez de Paterna L, Arnaiz F, Estenoz J, et al. Study of serum tumor markers CEA, CA15.3 and CA27.29 as diagnostic parameters in patients with breast carcinoma. Int J Biol Markers 1995;10:24-9.
84. Correale M, Abbate I, Gargano G, et al. Analytical and clinical evaluation of a new tumor marker in breast cancer: CA27.29. Int J Biol Markers 1992;7:43-6.
85. Sakamoto H, Yonezawa S, Utsunomiya T, et al. Mucin antigen expression in gastric carcinomas of young and old adults. Hum Pathol 1997;28:1056-65.
86. Baldus SE, Zirbes TK, Engel S, et al. Correlation of the immunohistochemical reactivity of mucin peptide cores MUC1 and MUC2 with the histopathological subtype and prognosis of gastric carcinomas. Int J Cancer 1998;79:133-8.
87. Utsunomiya T, Yonezawa S, Sakamoto H, et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 1998;4:2605-14.
88. Akyurek N, Akyol G, Dursun A, et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas: their relationship with clinicopathologic parameters and prognosis. Pathol Res Pract 2002;198:665-74.
89. Kocer B, Soran A, Kiyak G, et al. Prognostic significance of mucin expression in gastric carcinoma. Dig Dis Sci 2004;49:954-64.
90. Reis CA, David L, Seixas M, et al. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer 1998;79:402-10.
91. Tanaka M, Kitajima Y, Sato S, et al. Combined evaluation of mucin antigen and E-cadherin expression may help select patients with gastric cancer suitable for minimally invasive therapy. Br J Surg 2003;90:95-101.
92. Roessler K, Monig SP, Schneider PM, et al. Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis. World J Gastroenterol 2005;11:3182-8.
93. Filipe MI, Jass JR. Intestinal metaplasia subtypes and cancer risk. In: Filipe MI, Jass JR, eds. Gastric carcinoma. London: Churchill Livingstone, 1986:87-115.
94. Reis CA, David L, Carvalho F, et al. Immunohistochemical study of the expression of MUC6 mucin and co-expression of other secreted mucins (MUC5AC and MUC2) in human gastric carcinomas. J Histochem Cytochem 2000;48:377-88.
95. Baldus SE, Zirbes TK, Glossmann J, et al. Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer. Oncology 2001;61:147-55.
96. Chung YS, Yamashita Y, Kato Y, et al. Prognostic significance of T antigen expression in patients with gastric carcinoma. Cancer 1996;77:1768-73.
97. Nakamori S, Furukawa H, Hiratsuka M, et al. Expression of carbohydrate antigen sialyl Le(a): a new functional prognostic factor in gastric cancer. J Clin Oncol 1997;15:816-25.
98. Mayer B, Funke I, Johnson JP. High expression of a Lewis(x)-related epitope in gastric carcinomas indicates metastatic potential and poor prognosis. Gastroenterology 1996;111:1433-46.
99. Iwata H, Itzkowitz SH, Werther JL, et al. Expression of sialosyl-Tn in intestinal type cancer cells of human gastric cancers. Acta Pathol Jpn 1993;43:646-53.
100. Ferreira B, Marcos NT, David L, et al. Terminal α1,4-linked N-acetylglucosamine in Helicobacter pylori-associated intestinal metaplasia of the human stomach and gastric carcinoma cell lines. J Histochem Cytochem 2006;54:585-91.
101. Werther JL, Tatematsu M, Klein R, et al. Sialosyl-Tn antigen as a marker of gastric cancer progression: an international study. Int J Cancer 1996;69:193-9.
102. Byrd JC, Yan P, Sternberg L, et al. Aberrant expression of gland-type gastric mucin in the surface epithelium of Helicobacter pylori-infected patients. Gastroenterology 1997;113:455-64.
103. Ilver D, Arnqvist A, Ogren J, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998;279:373-7.
104. Linden S, Boren T, Dubois A, et al. Rhesus monkey gastric mucins: oligomeric structure, glycoforms and Helicobacter pylori binding. Biochem J 2004;379:765-75.
105. Marcos NT, Magalhaes A, Ferreira B, et al. Helicobacter pylori induces β3GnT5 in human gastric cell lines, modulating expression of the SabA ligand sialyl-Lewis x. J Clin Invest 2008;118:2325-36.
106. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333:32-41.
107. Rubio CA. A simple method to demonstrate duodenal gastric metaplasia. J Clin Pathol 2002;55:520-3.
108. Mall AS, McLeod H, Jaskiewicz K, et al. Putative glycosylated "linker" protein in mucin in gastric carcinoma. S Afr J Sci 1990;86:45-6.
109. Hakkinen I, Nevalainen T, Paasivuo R, et al. Gastric cancer associated structure in mucus glycoproteins shown as a clinically useful marker. Gut 1991;32:1465-9.
110. Mall AS, McLeod HA, Hickman R, et al. Fragmentation pattern of mucins in normal and diseased gastric mucosae: a glycoprotein fractionates with gastric mucins purified from mucosal scrapings of cancer and peptic ulcer patients. Digestion 1999;60:216-26.
111. Mall AS, McConney Z, Lotz Z, et al. Increased fragmentation of MUC5AC mucins in gastric juice of patients with ulceratioan and carcinoma. S Afr J Sci 2000;96:39-43.
112. Duche JC, Urien S, Simon N, et al. Expression of the genetic variants of human α-1-acid glycoprotein in cancer. Clin Biochem 2000;33:197-202.
113. Chauhan SC, Singh AP, Ruiz F, et al. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol 2006;19:1386-94.
114. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-5.
115. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
116. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003;21:200s-5s.
117. Llinares K, Escande F, Aubert S, et al. Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod Pathol 2004;17:150-7.
118. Guddo F, Giatromanolaki A, Koukourakis MI, et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998;51:667-71.
119. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res 2000;6:1917-21.
120. Sun AP, Ohtsuki Y, Fujita J, et al. KL-6, a human MUC1 mucin, is expressed early in premature lung. Respir Med 2003;97:964-9.
121. Hallstrand TS, Debley JS, Farin FM, et al. Role of MUC5AC in the pathogenesis of exercise-induced bronchoconstriction. J Allergy Clin Immunol 2007;119:1092-8.
122. Shibahara H, Tamada S, Higashi M, et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 2004;39:220-9.
123. Takao S, Uchikura K, Yonezawa S, et al. Mucin core protein expression in extrahepatic bile duct carcinoma is associated with metastases to the liver and poor prognosis. Cancer 1999;86:1966-75.
124. Mall AS, Hall P, Tyler M, et al. The expression of mucin in cholangiocarcinoma. Liver International 2006;26:22.
125. Higashi M, Yonezawa S, Ho JJ, et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 1999;30:1347-55.
126. Andren O, Fall K, Andersson SO, et al. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007;97:730-4.
127. Simms MS, Hughes OD, Limb M, et al. MUC1 mucin as a tumour marker in bladder cancer. BJU Int 1999;84:350-2.
128. Vinall LE, Fowler JC, Jones AL, et al. Polymorphism of human mucin genes in chest disease: possible significance of MUC2. Am J Respir Cell Mol Biol 2000;23:678-86.
129. Kirkbride HJ, Bolscher JG, Nazmi K, et al. Genetic polymorphism of MUC7: allele frequencies and association with asthma. Eur J Hum Genet 2001;9:347-54.
130. Rousseau K, Vinall LE, Butterworth SL, et al. MUC7 haplotype analysis: results from a longitudinal birth cohort support protective effect of the MUC7*5 allele on respiratory function. Ann Hum Genet 2006;70:417-27.
131. Kamio K, Matsushita I, Hijikata M, et al. Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronchiolitis. Am J Respir Crit Care Med 2005;171:949-57.
132. Vinall LE, King M, Novelli M, et al. Altered expression and allelic association of the hypervariable membrane mucin MUC1 in Helicobacter pylori gastritis. Gastroenterology 2002;123:41-9.
133. Silva F, Carvalho F, Peixoto A, et al. MUC1 gene polymorphism in the gastric carcinogenesis pathway. Eur J Hum Genet 2001;9:548-52.
134. Carvalho F, Seruca R, David L, et al. MUC1 gene polymorphism and gastric cancer - an epidemiological study. Glycoconj J 1997;14:107-11.
135. Kyo K, Muto T, Nagawa H, et al. Associations of distinct variants of the intestinal mucin gene MUC3A with ulcerative colitis and Crohn's disease. J Hum Genet 2001;46:5-20.